Weiguo Liu

This inventor holds 17 USPTO granted patents and 1 published patent application and 17 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc.. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Weiguo Liu. Retrieved from https://idiyas.com/inventor/weiguo-liu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 1)

% Patents Active = 94.1

EPO Patents = 17 (Patent Applications = 14)

Average Co-Inventor Count = 10.7

ph-index = 2

Forward Citations = 30(Granted Patents)

Location History:

Princeteon, NJ (US) (2019)
Princeton, NJ (US) (2008 - 2022)
Princeton Junction, NJ (US) (2017 - 2022)

Company Filing History:

16 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 2008-2022

Loading Chart...

Areas of Expertise:

Monobactam Compounds

LRRK2 Inhibitors

Pharmaceutical Compositions

Bacterial Infections

Factor XIa Inhibitors

Spiroxazolidinone Compounds

Antidiabetic Compounds

Bicyclic Amines

Tricyclic Compounds

Diabetes Treatment

Biaryl Compounds

Indazolyl Derivatives

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11433055 - Chromane monobactam compounds for the treatment of bacterial infections (2022-09-06),

2. 11230543 - Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2022-01-25),

3. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-16),

4. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),

5. 10407421 - Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2019-09-10),

6. 10214512 - Factor XIA inhibitors (2019-02-26),

7. 10123995 - Factor XIa inhibitors (2018-11-13),

8. 10093683 - Factor XIa inhibitors (2018-10-09),

9. 10081617 - Factor XIa inhibitors (2018-09-25),

10. 10011585 - Factor XIa inhibitors (2018-07-03),

11. 9868727 - Factor XIa inhibitors (2018-01-16),

12. 9809545 - Factor XIa inhibitors (2017-11-07),

13. 9783530 - Factor Xla inhibitors (2017-10-10),

14. 8759539 - Substituted bicyclic amines for the treatment of diabetes (2014-06-24),

15. 8742110 - Spiroxazolidinone compounds (2014-06-03),

Title: The Innovations of Weiguo Liu - Pioneering Monobactam Compounds for Bacterial Infections

Introduction: Weiguo Liu, a distinguished inventor based in Princeton, NJ, has made significant contributions to the field of pharmaceuticals with a focus on developing cutting-edge solutions for bacterial infections.

Latest Patents: Liu's recent patents include the groundbreaking Chromane Monobactam Compounds and Biaryl Monobactam Compounds. These inventions offer novel formulations and methods for the treatment of bacterial infections, showcasing his commitment to advancing healthcare through innovative pharmaceutical compounds.

Career Highlights: With an impressive portfolio of 17 patents, Weiguo Liu has demonstrated his expertise in the pharmaceutical industry. Having worked at prominent companies like Merck Sharp & Dohme Corporation and Merck & Company, Inc., Liu has honed his skills in research and development, paving the way for groundbreaking discoveries in the realm of antibacterial agents.

Collaborations: Throughout his career, Weiguo Liu has collaborated with esteemed professionals in the field, including coworkers such as Scott D. Edmondson and Wanying Sun. These partnerships have fostered a culture of innovation and knowledge-sharing, leading to the successful implementation of his patent inventions.

Conclusion: Weiguo Liu's inventive spirit and dedication to advancing healthcare technologies have positioned him as a leader in the development of monobactam compounds for the treatment of bacterial infections. His groundbreaking patents underscore his commitment to shaping a healthier future through pioneering pharmaceutical solutions.

Profile summary based on public USPTO records.